GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (FRA:5VA) » Definitions » YoY EBITDA Growth

Vaxcyte (FRA:5VA) YoY EBITDA Growth : -23.95% (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Vaxcyte YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Vaxcyte's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was -23.95%.

Vaxcyte's EBITDA per Share for the three months ended in Mar. 2024 was €-0.92.

Vaxcyte YoY EBITDA Growth Historical Data

The historical data trend for Vaxcyte's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vaxcyte YoY EBITDA Growth Chart

Vaxcyte Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial -76.90 -41.79 32.58 -89.31 -18.70

Vaxcyte Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -27.63 13.87 -46.96 -88.95 -23.95

Vaxcyte YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Vaxcyte's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-3.701--3.118)/ | -3.118 |
=-18.70 %

Vaxcyte's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

YoY EBITDA Growth (Q: Mar. 2024 )
=(EBITDA per Share (Q: Mar. 2024 )-EBITDA per Share (Q: Mar. 2023 )) / | EBITDA per Share (Q: Mar. 2023 )) |
=(-0.916--0.739)/ | -0.739 |
=-23.95 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vaxcyte YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Vaxcyte's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Vaxcyte (FRA:5VA) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vaxcyte Inc (FRA:5VA) » Definitions » YoY EBITDA Growth
Comparable Companies
HALO IMVT BBIO CERE ASND MRTX ABCZF ACAD IMGN INSM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
PCVX:USA
Address
825 Industrial Road, Suite 300, San Carlos, CA, USA, 94070
Website
https://www.vaxcyte.com
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from the most common and deadly diseases. Its product comprises. of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-24, VAX-XP, VAX-A1, and VAX-PG.

Vaxcyte (FRA:5VA) Headlines

No Headlines